179
3 Methods
1. Dissolve p-sulfonatocalix[4]arene in phosphate buffer pH 7.0
(10 μM).
2. Dilute TMZ in MeOH.
3. Add dropwise TMZ in the aqueous solution and magnetically
stir at room temperature for 1–2 h (see Note 1).
4. Remove MeOH under low pressure to precipitate the unencapsulated drug.
5. Filter contents through a nylon filter with 0.45 μm pore size.
6. In order to obtain the complex evaporate aqueous phase under
high vacuum.
3.1 Synthesis,
Characterization, and
Quantification of the
Encapsulated TMZ
3.1.1 Synthesis
and Purification
of Nanocapsule
Fig. 2
1
H-NMR spectra of PSC4 (green), TMZ (blue), and TMZ@PSC4 complex (red). The significant alteration
observed in the chemical shift of the H b proton of the imidazotetrazine ring of TMZ in the NMR spectrum of the
TMZ@calix complex concerning the native TMZ pinpoints that the imidazotetrazine ring of TMZ is incorporated
deep inside the hydrophobic cavity of calix
Encapsulation of Small Drugs in a Supramolecule Enhances Solubility, Stability…
3 Methods
1. Dissolve p-sulfonatocalix[4]arene in phosphate buffer pH 7.0
(10 μM).
2. Dilute TMZ in MeOH.
3. Add dropwise TMZ in the aqueous solution and magnetically
stir at room temperature for 1–2 h (see Note 1).
4. Remove MeOH under low pressure to precipitate the unencapsulated drug.
5. Filter contents through a nylon filter with 0.45 μm pore size.
6. In order to obtain the complex evaporate aqueous phase under
high vacuum.
3.1 Synthesis,
Characterization, and
Quantification of the
Encapsulated TMZ
3.1.1 Synthesis
and Purification
of Nanocapsule
Fig. 2
1
H-NMR spectra of PSC4 (green), TMZ (blue), and TMZ@PSC4 complex (red). The significant alteration
observed in the chemical shift of the H b proton of the imidazotetrazine ring of TMZ in the NMR spectrum of the
TMZ@calix complex concerning the native TMZ pinpoints that the imidazotetrazine ring of TMZ is incorporated
deep inside the hydrophobic cavity of calix
Encapsulation of Small Drugs in a Supramolecule Enhances Solubility, Stability…